1.	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-406/SARC021, NCT01440088
2.	Phase I/II Study of Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Patients With Advanced Renal Cell Carcinoma or Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N1153, N1153, NCT01497444
3.	Open-label Study of TH-302 as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-408, NCT01522872
4.	Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HSC20110360H, NCT01403610
5.	Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-407, NCT01149915
6.	Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TH-CR-410, NCT01381822
7.	Dose Escalation Study of Pazopanib Plus TH-302 Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00031123, NCT01485042